REX Shares recently launched the REX Peptide ETF (PEPT), a thematic fund offering global exposure to the peptide industry, from drug developers to manufacturers and delivery platforms. Inside PEPT ETF The REX Peptide ETF looks to track the VettaFi Peptide Index, comprising companies developing, manufacturing and delivering peptide-based medicines, along with the businesses using peptides in supplements and skincare. Eli Lilly (12.81%), Ascendis Pharma A/S Common Stock (10.26%) and Novo Nordisk A/S ADR (10.23%) take the top three spots in the fund. The fund charges 65 bps in fees.
We show the main point publicly. Create a free account to continue reading the full article, save it, discuss it, and connect it with market and OSINT context.